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Background
Atazanavir/r (ATV/r) is a recommended PI option for
treating ART-naive patients in recent guidelines. TDF/
FTC is the most commonly used recommended back-
bone in this setting. Our objectives were to compare
times 1) to discontinuation of the third drug, 2) to viro-
logic suppression (VL< 50 copies/ml), with discontinua-
tion of the third drug considered as failure, 3) to an
increase of at least 100 CD4 cells/mm
3, with disconti-
nuation of the third drug considered as failure, 4) to
AIDS or death from any cause, with an intention to
continue approach 5) to hospitalization, AIDS or death
with an intention to continue approach in patients initi-
ating with ATV/r or another recommended third drug
plus TDF/FTC.
Methods
ART-naive patients in the FHDH ANRS CO4 cohort
who started cART containing TDF/FTC plus either
ATV/r or another recommended third drug (LPV/r,
f-AMP/r or EFV) after 31/12/2003 and at least 12
month before the closing date of the database were ana-
lyzed. Multivariable Cox’s proportional hazards models
were used to control for the following potential con-
founders: Age, sex, geographical origin, transmission
group, baseline CD4 cell counts and viral load, AIDS
stage, HCV co-infection and year of starting.
Results
2910 patients (ATV/r=517 and Other=2393) were ana-
lyzed, with a median follow-up of 19.1 months (IQR:
9.8-30.4). The third drug was EFV in 1129 (47.2%),
LPV/r in 1045 (43.7%) and f-APV/r in 219 (9.2%). Base-
line median CD4 was 246 for ATV/r and 228 for other
drugs (p=0.0064) and viral load 4.87 for ATV/r and 4.89
for other drugs (p=0.0688). At 24 months, the rates of
the different outcomes were for ATV/r versus other
drugs:
￿ Discontinuation of the 3rd drug: 24% and 27% (aHR:
0.76 (0.61-0.94))
￿ Virologic suppression (VL< 50 copies/ml): 83% and
84% (aHR: 0.93 (0.84-1.04))
￿ Increase of at least 100 CD4 cells/mm
3:8 3 %a n d
80% (aHR: 1.09 (0.98-1.21))
￿ AIDS or death: 7% and 10% (aHR: 0.88 (0.61-1.28))
￿ Hospitalization, AIDS or death: 17% and 21% (aHR:
0.93 (0.73-1.18))
Sensitivity analyses using propensity scores and sub-
group analyses in patients with CD4<200/mm
3 depend-
ing of the level of viral load (< or >=100 000 copies/ml)
will also be presented.
Conclusions
In this observational settings in ART-naive patients, use
of ATV/r as third drug was associated with a lower rate
of discontinuation and with no difference in terms of
virologic suppression, immunological and clinical out-
comes as compared to other recommended third drugs.
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